PIK3R1 Protein (p85α)

PIK3R1 Protein (p85α - Phosphoinositide-3-Kinase Regulatory Subunit 1)

Introduction

PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1), commonly known as p85α, is the major regulatory subunit of class IA phosphoinositide 3-kinases (PI3Ks). This critical signaling protein plays essential roles in cellular growth, survival, metabolism, and synaptic function. Dysregulation of p85α and PI3K/Akt signaling is strongly implicated in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and stroke. This page provides comprehensive information about p85α structure, function, and its involvement in neurodegeneration.

<div class="infobox .infobox-protein">
| | |
|---|---|
| Protein Name | Phosphoinositide-3-Kinase Regulatory Subunit 1 (p85α) |
| Gene Symbol | [PIK3R1](/genes/pik3r1) |
| UniProt ID | [P27986](https://www.uniprot.org/uniprot/P27986) |
| Molecular Weight | 85 kDa |
| Amino Acids | 724 |
| Subcellular Localization | Cytoplasm, plasma membrane, endosomes |
| Protein Family | PI3K regulatory subunit (p85) family |
| Brain Expression | [Cortex](/brain-regions/cortex), [Hippocampus](/brain-regions/hippocampus), Cerebellum, Basal ganglia |
| PDB Structure | [4A0B](https://www.ebi.ac.uk/pdbe/entry/pdb/4A0B), [4JPS](https://www.ebi.ac.uk/pdbe/entry/pdb/4JPS), [4OVU](https://www.ebi.ac.uk/pdbe/entry/pdb/4OVU) |
</div>

Overview

PIK3R1 Protein (p85α - Phosphoinositide-3-Kinase Regulatory Subunit 1)

Introduction

PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1), commonly known as p85α, is the major regulatory subunit of class IA phosphoinositide 3-kinases (PI3Ks). This critical signaling protein plays essential roles in cellular growth, survival, metabolism, and synaptic function. Dysregulation of p85α and PI3K/Akt signaling is strongly implicated in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and stroke. This page provides comprehensive information about p85α structure, function, and its involvement in neurodegeneration.

<div class="infobox .infobox-protein">
| | |
|---|---|
| Protein Name | Phosphoinositide-3-Kinase Regulatory Subunit 1 (p85α) |
| Gene Symbol | [PIK3R1](/genes/pik3r1) |
| UniProt ID | [P27986](https://www.uniprot.org/uniprot/P27986) |
| Molecular Weight | 85 kDa |
| Amino Acids | 724 |
| Subcellular Localization | Cytoplasm, plasma membrane, endosomes |
| Protein Family | PI3K regulatory subunit (p85) family |
| Brain Expression | [Cortex](/brain-regions/cortex), [Hippocampus](/brain-regions/hippocampus), Cerebellum, Basal ganglia |
| PDB Structure | [4A0B](https://www.ebi.ac.uk/pdbe/entry/pdb/4A0B), [4JPS](https://www.ebi.ac.uk/pdbe/entry/pdb/4JPS), [4OVU](https://www.ebi.ac.uk/pdbe/entry/pdb/4OVU) |
</div>

Overview

p85α is encoded by the PIK3R1 gene and serves as the principal regulatory subunit of class IA PI3Ks. The protein regulates the catalytic p110 subunit (p110α, p110β, p110δ) by controlling its localization, stability, and enzymatic activity. p85α contains multiple protein-protein interaction domains that allow it to couple activated cell surface receptors to intracellular signaling cascades[@yu1998].

Protein Structure

Domain Architecture

p85α (724 amino acids) contains several distinct domains:

• N-terminal SH3 domain (1-85): Binds proline-rich sequences via PXXP motifs
• Bcr homology domain (85-300): Contains the inter-SH2 (iSH2) region critical for p110 binding
• iSH2 domain (300-500): Forms the main interface with p110 catalytic subunit
• C-terminal SH2 domain (cSH2) (600-620): Binds phosphotyrosine motifs on activated receptors
• N-terminal SH2 domain (nSH2) (330-420): Regulates p110 activity

Structural Features

• Molecular weight: ~85 kDa
• Isoforms: p85α, p55α (pik3r1 splice variant), p50α
• Post-translational modifications: Phosphorylation (Y459, Y467), ubiquitination

Normal Function

PI3K Activation and Regulation

p85α is essential for PI3K function:

Signaling Pathways

• PI3K/Akt pathway: Major downstream effector of p85α-regulated PI3K
• [mTOR](/entities/mtor) pathway: Akt activates mTORC1 for protein synthesis
• [GSK-3β](/entities/gsk3-beta) regulation: Akt phosphorylates and inhibits GSK-3β
• FOXO transcription factors: Akt phosphorylates FOXO, promoting its cytoplasmic retention

Cellular Processes

• Cell survival: Akt-mediated inhibition of pro-apoptotic proteins (Bad, caspase-9)
• Metabolism: Insulin signaling, GLUT4 translocation, lipid synthesis
• Protein synthesis: mTORC1 activation
• Cell growth: Ribosome biogenesis and translation
• Synaptic plasticity: [NMDA](/entities/nmda-receptor) receptor trafficking, AMPA receptor insertion

Brain Functions

• Neuronal survival: Neurotrophic factor signaling (BDNF, NGF)
• Synaptic plasticity: [Long-term potentiation](/mechanisms/long-term-potentiation) (LTP) and memory formation
• Metabolic regulation: Neuronal glucose uptake
• Axonal guidance: Growth cone dynamics

Role in Neurodegeneration

Alzheimer's Disease

p85α and PI3K signaling are prominently affected in AD:

• Reduced p85α expression: Decreased levels in AD hippocampus and cortex
• Impaired Akt signaling: Downstream of p85α, Akt activity is reduced
• [Tau](/proteins/tau) pathology: PI3K/Akt normally inhibits GSK-3β; loss promotes [tau](/proteins/tau) hyperphosphorylation
• Amyloid-beta effects: [Aβ](/proteins/amyloid-beta) disrupts insulin-PI3K-Akt signaling
• Synaptic failure: PI3K is critical for synaptic plasticity; dysfunction contributes to memory deficits
• Neuronal survival: Reduced neuroprotection against Aβ toxicity

Parkinson's Disease

• Dopaminergic neuron survival: PI3K/Akt is critical for nigral neuron survival
• LRRK2 interactions: Pathogenic LRRK2 affects PI3K pathway signaling
• [α-Synuclein](/proteins/alpha-synuclein) pathology: PI3K/Akt dysfunction may sensitize [neurons](/entities/neurons) to α-synuclein toxicity
• Neurotrophic factors: GDNF signaling relies on PI3K/Akt

Amyotrophic Lateral Sclerosis (ALS)

• Motor neuron survival: PI3K/Akt pathway promotes motor neuron viability
• Glutamate excitotoxicity: PI3K signaling can counteract excitotoxic cell death
• Mitochondrial function: PI3K helps maintain mitochondrial health

Stroke and Ischemia

• Ischemic preconditioning: PI3K/Akt activation is neuroprotective
• Reperfusion injury: PI3K signaling can reduce oxidative damage
• Angiogenesis: PI3K promotes blood vessel formation post-stroke

Metabolic Disorders

• Type 2 diabetes link: p85α mutations/dysfunction may increase AD risk
• Insulin resistance: [Brain insulin signaling](/entities/brain-insulin-signaling) impairment in both T2D and AD

Therapeutic Implications

PI3K/Akt Pathway Modulators

| Drug/Compound | Target | Development Stage | Potential Use |
|---------------|--------|-------------------|---------------|
| Wortmannin | PI3K (irreversible) | Research tool | Lab studies |
| LY294002 | PI3K (reversible) | Research tool | Lab studies |
| Idelalisib | p110δ | Approved (oncology) | Under investigation |
| Alpelisib | p110α | Approved (oncology) | May benefit brain |
| Metformin | AMPK activation | Approved (diabetes) | Under investigation for AD |

Challenges

• Broad pathway effects: Systemic PI3K inhibition causes metabolic dysfunction
• [Blood-brain barrier](/entities/blood-brain-barrier): Drug delivery to CNS is challenging
• Biphasic effects: Constitutive activation can be oncogenic

Therapeutic Strategies

• p85α modulators: Developing compounds that enhance p85α function
• Akt activators: Direct Akt activation bypasses p85 dysfunction
• Neurotrophic factors: BDNF mimetics that activate PI3K

Therapeutic Implications

PI3K/Akt Pathway Modulators

| Drug/Compound | Target | Development Stage | Potential Use |
|---------------|--------|-------------------|---------------|
| Wortmannin | PI3K (irreversible) | Research tool | Lab studies |
| LY294002 | PI3K (reversible) | Research tool | Lab studies |
| Idelalisib | p110δ | Approved (oncology) | Under investigation |
| Alpelisib | p110α | Approved (oncology) | May benefit brain |
| Metformin | AMPK activation | Approved (diabetes) | Under investigation for AD |

Challenges

• Broad pathway effects: Systemic PI3K inhibition causes metabolic dysfunction
• Blood-brain barrier: Drug delivery to CNS is challenging
• Biphasic effects: Constitutive activation can be oncogenic

Therapeutic Strategies

• p85α modulators: Developing compounds that enhance p85α function
• Akt activators: Direct Akt activation bypasses p85 dysfunction
• Neurotrophic factors: BDNF mimetics that activate PI3K

Role in ALS

• Motor neuron survival: PI3K/Akt pathway promotes motor neuron viability
• Glutamate excitotoxicity: PI3K signaling can counteract excitotoxic cell death
• Mitochondrial function: PI3K helps maintain mitochondrial health

Role in Stroke and Ischemia

• Ischemic preconditioning: PI3K/Akt activation is neuroprotective
• Reperfusion injury: PI3K signaling can reduce oxidative damage
• Angiogenesis: PI3K promotes blood vessel formation post-stroke

Cross-Links

• [PIK3R1 Gene](/genes/pik3r1)
• [PIK3CA Protein (p110α)](/proteins/pik3ca-protein)
• [PI3K-AKT Pathway](/mechanisms/pi3k-akt-pathway)
• [mTOR Pathway](/mechanisms/mtor-pathway)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [GSK-3β Mechanisms](/mechanisms/gsk-3-beta)
• [Synaptic Plasticity Mechanisms](/mechanisms/synaptic-plasticity)

See Also

• [Akt Protein (AKT1)](/proteins/akt1-protein)
• [mTOR Protein](/proteins/mtor-protein)
• [IRS Proteins](/entities/irs-proteins)
• [PDK1 Protein](/proteins/pdk1-protein)
• [PTEN Protein](/proteins/pten-protein) — negative regulator

References